A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Consumer Confidence Report
U.S. stock futures traded mostly lower in early pre-market trade. The S&P/Case-Shiller home price index for June will be released at 9:00 a.m. ET, while the Conference Board's consumer confidence index for August is schedule for release at 10:00 a.m. ET.
Futures for the Dow Jones Industrial Average fell 1 point to 18,488.00, while the Standard & Poor’s 500 index futures fell 0.75 points to 2,178.75. Futures for the Nasdaq 100 index declined 8.25 points to 4,785.00.
Oil prices traded higher as Brent crude futures gained 0.53 percent to trade at $49.52 per barrel, while US WTI crude futures also rose 0.70 percent to trade at $47.31 a barrel.
A Peek Into Global Markets
European markets were higher today, with the Spanish Ibex Index rising 0.69 percent, STOXX Europe 600 Index gaining 0.44 percent and German DAX 30 index gaining 0.87 percent. The UK's FTSE index was trading higher by 0.03 percent, while French CAC 40 Index climbed 0.76 percent.
In Asian markets, Japan’s Nikkei Stock Average fell 0.07 percent, Hong Kong’s Hang Seng Index rose 0.85 percent, China’s Shanghai Composite Index gained 0.15 percent and India’s BSE Sensex gained 1.58 percent.
Analysts at Baird upgraded McDonald's Corporation (NYSE: MCD) from Neutral to Outperform.
McDonald's shares fell 0.10 percent to $115.30 in pre-market trading.
- G-III Apparel Group, Ltd. (NASDAQ: GIII) reported weaker-than-expected results for its second quarter and lowered its full-year guidance.
- Shares of Apple Inc. (NASDAQ: AAPL) fell more than 2 percent Tuesday morning after the European Union slapped the company with a whopping 13 billion euro ($14.5 billion) bill for back taxes. The EU concluded that Ireland gave Apple illegal state aid over many years. To read the full news, click here.
- Christopher & Banks Corporation (NYSE: CBK) posted a wider-than-expected loss for the second quarter on Tuesday.
- Kamada Ltd (NASDAQ: KMDA) disclosed favorable top-line results of its second stage trial on inhaled Alpha-1 Antitrypsin that met primary endpoint. To read the full news, click here.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.